Protagonist Therapeutics Announces FDA Approval For ICOTYDE, IL-23 Receptor Antagonist For Treatment Of Moderate-To-Severe Plaque Psoriasis; Treatment Commercialized Under License By Johnson & Johnson - Johnson & Johnson (NYSE:JNJ), Protagonist Therapeutics (NASDAQ:PTGX)
Published on March 18, 2026.
The FDA has approved the use of the ICOTYDE, IL-23 Receptor Antagonist for the treatment of Moderate-To-Severe Plaque Psoriasis. The drug is being commercialized under a license agreement with Johnson & Johnson.
Related Articles
Tigress Financial Maintains Strong Buy on Meta Platforms, Raises Price Target to $945 - Meta Platforms (NASDAQ:META)
Tigher-Sheepen (formerly known as "Ethic" is the name of the day: An article by Steve N.
Telsey Advisory Group Maintains Market Perform on Macy's, Maintains $25 Price Target - Macy's (NYSE:M)
The article is published here:.
The stock market is quickly losing momentum and Fed decision won't help
The stock market is losing momentum as the S & P 500 struggles with rising volatility and a potential rise in US-Iran war-related tensions, with few expectations of interest rate cuts.